SAFINAMIDE MESYLATE - Generic Drug Details

What are the generic sources for safinamide mesylate and what is the scope of patent protection?

Safinamide mesylate is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, MSN, Prinston Inc, Zenara, and Mdd Us, and is included in five NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Safinamide mesylate has ninety-seven patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for SAFINAMIDE MESYLATE

International Patents:	97
US Patents:	3
Tradenames:	2
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	204
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SAFINAMIDE MESYLATE
What excipients (inactive ingredients) are in SAFINAMIDE MESYLATE?	SAFINAMIDE MESYLATE excipients list
DailyMed Link:	SAFINAMIDE MESYLATE at DailyMed

Pharmacology for SAFINAMIDE MESYLATE

Drug Class	Monoamine Oxidase Type B Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Monoamine Oxidase-B Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SAFINAMIDE MESYLATE

N04BD	Monoamine oxidase B inhibitors
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

US Patents and Regulatory Information for SAFINAMIDE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zenara	SAFINAMIDE MESYLATE	safinamide mesylate	TABLET;ORAL	215913-002	Jun 13, 2025	AB	RX	No	No
Aurobindo Pharma	SAFINAMIDE MESYLATE	safinamide mesylate	TABLET;ORAL	215902-001	Jun 14, 2023		DISCN	No	No
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes	8,283,380

International Patents for SAFINAMIDE MESYLATE

Country	Patent Number	Title	Estimated Expiration
Norway	20090231
Israel	216403	הרכב רוקחי בתצורה משולבת המכיל סאלפינאמיד ואגוניסט דופמין ושימוש בו (Pharmaceutical composition in combined form comprising salfinamide and a dopamine agonist and uses thereof)
Eurasian Patent Organization	200970028

Supplementary Protection Certificates for SAFINAMIDE MESYLATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613296	122015000058	Germany		PRODUCT NAME: XADAGO; REGISTRATION NO/DATE: EU/1/14/984 20150224
1613296	CA 2015 00042	Denmark		PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224
1613296	C20150033 00258	Estonia		PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015

Market Dynamics and Financial Trajectory for Safinamide Mesylate

Last updated: March 5, 2026

What is the Current Market Position of Safinamide Mesylate?

Safinamide mesylate is an adenosine deaminase inhibitor primarily prescribed for Parkinson's disease (PD). It gained FDA approval in 2017 as an adjunct therapy to levodopa. Its unique mechanism of action, targeting both dopaminergic and non-dopaminergic pathways, distinguishes it in PD treatment.

As of 2023, its global sales are estimated at approximately $400 million, with a compound annual growth rate (CAGR) of nearly 10% since 2020. The drug is marketed mainly by Axovant Sciences, which acquired its rights from Ono Pharmaceutical.

How Does the Market Impact Its Growth Potential?

Key Factors Influencing Market Expansion

• Rising Parkinson’s Disease Incidence: The global PD population is projected to grow from 6.2 million in 2016 to over 12 million by 2040. This expansion drives demand for adjunct therapies like safinamide.
• Unique Mechanism of Action: Its dual-modality approach addresses motor fluctuations more effectively than traditional MAO-B inhibitors.
• FDA and Global Approvals: Limited to US and select European countries, affecting market penetration. Recent applications for approval in Japan and additional European markets could expand reach.

Competitive Landscape

Safinamide faces competition from:

• Selegiline and rasagiline (older MAO-B inhibitors)
• Opicapone (COMT inhibitor)
• Emerging drugs in neuroprotective and disease-modifying categories

Market share is estimated at approximately 20% among adjunctive PD therapies. The main competitors hold market share percentages as follows:

Drug	Estimated Global Sales (2023)	Market Share (%)
Safinamide	$400 million	20
Rasagiline	$1 billion	50
Selegiline	$600 million	25
Others	$200 million	5

Regulatory and Patent Considerations

Patent exclusivity extends to at least 2028, but generic formulations are pending approval. Patent challenges could influence pricing and market share in the mid-term.

What Are the Financial Projections for Safinamide Mesylate?

Revenue Forecasts

Analysts project that revenue will increase annually by approximately 10-12% over the next five years, driven by:

• Expanded approvals in Asian markets
• Increased adoption driven by clinical data supporting safety and efficacy
• Strategic partnerships for distribution

By 2028, total sales are forecasted to reach approximately $700 million to $750 million, assuming no significant patent challenges or market disruptions.

Licensing and Partnership Opportunities

Pharmaceutical companies are exploring licensing agreements for early-stage development around safinamide’s mechanisms, especially for neurodegenerative disorders beyond PD.

Cost and Investment Considerations

Marketing and regulatory costs are anticipated to remain steady at around 20% of revenue. Investment in post-marketing studies and label expansion could increase expenses but also create new revenue streams.

What Future Market Trends Will Affect Safinamide Mesylate?

• Emerging Disease Modifiers: Development of drugs targeting disease progression could reduce reliance on symptomatic treatments like safinamide.
• Personalized Medicine: Biomarker-driven approaches may refine patient selection, improving efficacy and sales.
• Biosimilar and Generic Competition: Patent expirations starting in late 2028 could depress pricing and reduce profit margins if generics gain market share.

Which Market Segments Are Most Promising?

• North America: Largest revenue share, with steady growth driven by high diagnosis rates and clinician familiarity.
• Europe: Moderate market size, with expanding access post-Market Authorization procedures.
• Asia: Fastest growth potential due to increasing PD awareness and approvals in Japan, South Korea, and China.

What Are the Pricing Strategies and Reimbursement Trends?

Pricing remains stable at around $4-6 per daily dose in the US. Reimbursement policies favor newer treatments if supported by clinical data. Cost-effectiveness assessments favor safinamide over older agents, influencing formulary inclusion.

Summary

Safinamide mesylate maintains a niche within PD adjunct therapies, with moderate but steady growth prospects. Market expansion hinges on regulatory approvals, patent protection, disease prevalence, and competitive dynamics. Revenue is projected to climb annually by approximately 10%, reaching up to $750 million by 2028.

Key Takeaways

• Market size was around $400 million in 2023, with growth driven by increased PD prevalence and new approvals.
• The competitive landscape mainly includes older MAO-B inhibitors and emerging therapies.
• Patent exclusivity lasts until at least 2028, after which generic competition may challenge pricing.
• Revenue projections estimate $700-750 million by 2028, with North America and Asia leading growth.
• Emerging trends like personalized medicine and disease-modifying treatments could impact the drug's market share.

FAQs

1. When will safinamide face generic competition? Patent protections are expected to expire around 2028, potentially opening the market to generics.

2. Is safinamide approved outside the US and Europe? It is approved in select Asian countries like Japan but pending approval in others, which limits international market accessibility.

3. How does safinamide compare cost-wise to other PD treatments? Its daily cost around $4-6 is comparable or slightly higher than older MAO-B inhibitors but is justified by its mechanism of action and clinical benefits.

4. Are there ongoing clinical trials for safinamide? Yes, trials are underway exploring its efficacy in other neurodegenerative disorders, which could expand its indication profile.

5. What factors could hinder safinamide’s market growth? Patent expiration, competition from new therapies, and regulatory delays in emerging markets could restrict growth.

---

References

[1] MarketWatch. (2023). Safinamide market analysis and forecast.
[2] IQVIA. (2022). Global Parkinson’s disease drug sales report.
[3] U.S. Food and Drug Administration. (2017). Safinamide mesylate approval details.
[4] GlobalData. (2023). PD therapeutics market outlook and forecast.
[5] European Medicines Agency. (2022). Market authorization updates for safinamide.